Specialties

The multidisciplinary synthetic therapy on lung cancer from basic science to bedside and evidence-based medicine in oncology.

Clinical Interests

Her main research interests include the multidisciplinary comprehensive treatment of lung cancer, mainly in targeted therapy and immunotherapy.

Her main research interests include the multidisciplinary comprehensive treatment of lung cancer, mainly in targeted therapy and immunotherapy.

She has a deep research on the precision treatment of lung cancer under the guidance of biomarkers, resistance mechanisms of targeted therapy and strategies to overcome drug resistance, and master the progression of diagnosis and treatment of lung cancer.

Besides, she has participated in more than 120 multicenter clinical trials in lung cancer, has acted as Principal Investigator (PI) of 28 clinical trials, and has given reports at domestic and international academic conferences for many times.

Experience Has been working in Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital since 2006.

Education Received Ph.D. degree in oncology at Sun Yat-sen University in 2006, and visited the Cancer Center of the University of Colorado in United States in 2009.

Awards and Honors Obtained second prize of National Scientific and Technological Progress Award, first prize of China Medical Science and Technology award, first prize and second prize of Guangdong Science and Technology award. Awarded “The National Bearer of Red Flag March 8”,

“The National Woman Pacesetter”, “The Guangzhou Pearl River New-star of Science and Technology”, “Guangdong Province's first batch of medical leaders and outstanding young medical talents”.

Professional memberships

Vice-chairman and secretary-general of Chinese Thoracic Oncology Group (CTONG).

Deputy secretary-general of Chinese Society Clinical Oncology (CSCO)

Chairman of the Lung Cancer Committee of the Guangdong Medical Women’s Association

Chairman of the Lung Cancer Committee of the Guangdong of Primary Medicine

Publications Published

more than 80 SCI research papers, including 26 papers as first-author or corresponding author, and one of them was published in Nature Review Drug Discovery (IF=53).